THROMBOSIS AND HAEMOSTASIS

Scope & Guideline

Elevating Knowledge in Thrombosis Research

Introduction

Welcome to the THROMBOSIS AND HAEMOSTASIS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of THROMBOSIS AND HAEMOSTASIS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0340-6245
PublisherGEORG THIEME VERLAG KG
Support Open AccessNo
CountryGermany
TypeJournal
Convergefrom 1976 to 2024
AbbreviationTHROMB HAEMOSTASIS / Thromb. Haemost.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRUDIGERSTR 14, D-70469 STUTTGART, GERMANY

Aims and Scopes

The journal 'Thrombosis and Haemostasis' focuses on advancing the understanding of thrombosis and hemostasis through the publication of high-quality research. It encompasses a wide range of topics related to blood coagulation, platelet function, vascular biology, and the management of thrombotic disorders.
  1. Thrombosis and Hemostasis Mechanisms:
    The journal emphasizes research on the underlying biological mechanisms of thrombosis and hemostasis, exploring the molecular, cellular, and genetic factors that contribute to these processes.
  2. Clinical Outcomes and Management Strategies:
    A significant focus is placed on clinical studies that assess the effectiveness of various anticoagulant therapies, management strategies for patients with thrombotic disorders, and the implications of these treatments on patient outcomes.
  3. Innovative Therapeutic Approaches:
    The journal highlights studies that explore novel therapeutic approaches for managing thrombotic and bleeding disorders, including the development of new anticoagulants and antiplatelet agents.
  4. Risk Assessment and Predictive Modeling:
    Research on risk factors and predictive models for thrombotic events is a key area of interest, aiming to improve risk stratification and patient management.
  5. Translational Research:
    The journal publishes findings that bridge basic science and clinical practice, facilitating the translation of laboratory discoveries into therapeutic applications for patients with thrombotic disorders.
The field of thrombosis and hemostasis is evolving, and recent publications in 'Thrombosis and Haemostasis' reveal several emerging trends and themes reflecting current research priorities and advancements in the field.
  1. COVID-19 and Thrombosis:
    A significant increase in research focusing on the relationship between COVID-19 and thrombotic events highlights the pandemic's impact on thrombosis research, emphasizing the need for understanding coagulopathy in infected patients.
  2. Personalized Medicine in Anticoagulation:
    Emerging studies emphasize the importance of personalized approaches to anticoagulation therapy, including tailoring treatments based on genetic, phenotypic, and clinical characteristics of patients.
  3. Machine Learning and Predictive Analytics:
    The integration of machine learning techniques for predicting thrombotic events and optimizing treatment strategies is gaining traction, reflecting a broader trend towards data-driven decision-making in healthcare.
  4. Cancer-Associated Thrombosis:
    Research specifically addressing the complexities of thrombosis in cancer patients is increasingly prevalent, focusing on the unique risk factors and management strategies required for this population.
  5. Innovative Biomarkers:
    There is a growing emphasis on identifying and validating novel biomarkers for predicting thrombosis and bleeding risks, which may enhance risk stratification and personalized treatment approaches.

Declining or Waning

While 'Thrombosis and Haemostasis' continues to publish a diverse array of topics, certain themes appear to be declining in prominence over recent years. This shift may reflect changes in research priorities or advancements in understanding that render previous topics less central to current discourse.
  1. Traditional Anticoagulant Therapies:
    There is a noticeable reduction in studies focused solely on traditional anticoagulant therapies such as warfarin, as newer agents like direct oral anticoagulants (DOACs) gain prominence in research.
  2. Basic Science of Hemostasis:
    Research that solely focuses on the basic science of hemostasis without practical clinical applications appears to be less frequent, as the journal shifts towards more clinically relevant studies.
  3. Static Risk Factor Studies:
    Studies that merely catalog risk factors without integrating them into predictive models or clinical applications are becoming less common, reflecting a trend towards more dynamic and actionable research.
  4. Single-Center Studies:
    There appears to be a decline in the publication of single-center studies as multi-center and larger cohort studies become the norm, likely due to the increased need for robust data in diverse populations.
  5. Pharmacokinetics of Established Drugs:
    Research focusing on the pharmacokinetics of well-established anticoagulants without new insights or comparative analyses is becoming less frequent, as emphasis shifts to novel agents and their clinical implications.

Similar Journals

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Exploring the frontiers of cardiovascular medicine and innovation.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1079-5642Frequency: 12 issues/year

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

CLINICAL HEMORHEOLOGY AND MICROCIRCULATION

Enhancing Understanding, Inspiring Clinical Applications
Publisher: IOS PRESSISSN: 1386-0291Frequency: 8 issues/year

Clinical Hemorheology and Microcirculation, published by IOS Press, is a distinguished journal dedicated to advancing the scientific understanding of blood flow mechanics and microcirculatory phenomena. Since its inception in 1991, the journal has been pivotal in bridging the fields of cardiology, hematology, and physiology, as evidenced by its placement in the Q3 quartile across several categories in 2023. Positioned in the vibrant academic landscape of the Netherlands, Clinical Hemorheology and Microcirculation offers valuable insights to researchers and practitioners alike, enriching their knowledge and fostering innovation in clinical practices. With an ISSN of 1386-0291 and an E-ISSN of 1875-8622, the journal serves as a vital platform for disseminating high-quality research and reviews that explore the intricate dynamics of blood viscosity and microvascular function, essential to both health and disease. As readers delve into the journal, they will access rigorous studies that not only enhance theoretical understanding but also pave the way for potential clinical applications, making it a crucial resource for those invested in the future of cardiovascular and hematological research.

Research and Practice in Thrombosis and Haemostasis

Innovating hematology through open-access insights.
Publisher: ELSEVIERISSN: Frequency: 8 issues/year

Research and Practice in Thrombosis and Haemostasis, published by Elsevier, is a prominent open-access journal dedicated to advancing the field of hematology through high-quality research and clinical practice. Since its inception in 2017, this journal has established itself as a vital resource for researchers, healthcare professionals, and students interested in thrombosis and hemorrhage management, showcasing original research, reviews, and clinical studies. The journal’s commitment to accessible knowledge is reflected in its open-access model, allowing researchers worldwide to share their findings without financial barriers. With an impressive 2023 Scopus rank of #42 out of 137 in the hematology category and a respectable Q2 classification, it provides an authoritative platform for innovative ideas and cutting-edge developments in the field. As the journal continues to grow in stature, it aims to foster collaboration and knowledge exchange amongst professionals dedicated to improving patient outcomes in thrombosis and hemostasis.

HemaSphere

Connecting researchers, clinicians, and students in hematology.
Publisher: WILEYISSN: Frequency: 12 issues/year

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Championing Excellence in Hematology Research
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Pioneering insights in cardiovascular health.
Publisher: SPRINGERISSN: 0929-5305Frequency: 8 issues/year

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.

Indian Journal of Vascular and Endovascular Surgery

Pioneering Research for the Future of Endovascular Surgery
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0972-0820Frequency: 4 issues/year

The Indian Journal of Vascular and Endovascular Surgery, published by Wolters Kluwer Medknow Publications, serves as a premier platform dedicated to advancing research and clinical practices in the fields of vascular and endovascular surgery. With an E-ISSN of 2394-0999 and a commitment to open access since 2015, this journal provides invaluable insights to researchers, professionals, and students alike, fostering a collaborative environment for the dissemination of knowledge. By focusing on innovative techniques, case studies, and systematic reviews, the journal plays a vital role in enhancing clinical outcomes and promoting evidence-based practices within the vascular community. Its commitment to high-quality research and accessibility positions it as an essential resource in the landscape of surgical literature, encouraging further exploration and collaboration within this critical area of healthcare.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Empowering Clinicians with Groundbreaking Findings
Publisher: ELSEVIER SCIENCE INCISSN: 1538-7933Frequency: 12 issues/year

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, published by Elsevier Science Inc, stands at the forefront of research in the fields of hematology and medicine, boasting an impressive ranking of #5 out of 137 in Scopus's Medicine - Hematology category, with a remarkable 96th percentile. As an essential resource for researchers, clinicians, and students, this journal, identifiable through its ISSN 1538-7933 and E-ISSN 1538-7836, encompasses pioneering studies and reviews that focus on the mechanisms of thrombosis and hemostasis, contributing significantly to advancements in patient care and therapeutic strategies. With an established presence from 2003 through 2024, it has consistently achieved a prestigious Q1 category ranking, reflecting its impactful contributions to the scientific community. Although it operates under a subscription-based model, the journal remains committed to disseminating significant findings that inform best practices in clinical settings and shape future research trajectories.

VASCULAR PHARMACOLOGY

Unlocking the mysteries of vascular biology and therapeutics.
Publisher: ELSEVIER SCIENCE INCISSN: 1537-1891Frequency: 12 issues/year

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Journal of Blood Medicine

Connecting Minds: Bridging Research and Clinical Practice in Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.